👋
Is this profile yours? Take control to keep your details current, set fees, and respond to reviews.
This page is aggregated from public sources.
Claim this profile →
Trust score 8/100
Accepting new patients
Prof
Prof Angus Dalgleish
Oncology
English
8,454+
Patients seen
15
Years in practice
13
Publications
1
Languages spoken
About
Professor Angus Dalgleish studied medicine at University College London where he obtained an MBBS and a BSc in Anatomy. He is a Fellow of The Royal College of Physicians of the UK and Australia, Royal College of Pathologists and The Academy of Medical Scientists. After graduating and house jobs in London and Poole, he spent a year in the flying doctor service in Queensland. He also trained in Internal Medicine and Oncology in Brisbane and Sydney. Having developed an interest in how viruses caused cancer, he commenced an MD with Professor Robin Weiss, FRS at the Institute of Cancer Research and Royal Marsden Hospital.
Following five years as a clinical scientist at the MRC's clinical research centre in Northwick Park, Professor Dalgleish was appointed to the Foundation Chair in Oncology at the St George's University of London in 1991. There his main interest has been the immunology of cancer and the development of immunotherapies to treat, in particular, melanoma. He is a co-founder of Onyvax, a company set up in 1998 to make novel vaccines for common solid tumours, where he is currently Research Director.
Professor Dalgleish currently sits on eight editorial boards and is the author or co-author of peer-reviewed scientific papers and over 70 chapters in medical books. He is the co-editor of five medical books and has been on numerous grant committees and is currently on the European Commission Cancer Board.
Diseases, Medical Tests and Treatments
• Kidney
• Pancreatic and prostate cancers
• Melanoma (chemotherapy)
• Breast cancer
• Gastrointestinal cancers
• Urological cancers
• Lung
• Skin cancer
• Sarcoma cancer
• Upper gastrointestinal cancers
• Lower gastrointestinal cancers
• Kidney cancer
• Prostate cancer
• Small cell lung cancer
• Non-small cell lung
• Other types of lung cancer
• Melanoma
• Kidney
• Pancreatic and prostate cancers
• Melanoma (chemotherapy)
• Breast cancer
• Gastrointestinal cancers
• Urological cancers
• Lung
• Skin cancer
• Sarcoma cancer
• Upper gastrointestinal cancers
• Lower gastrointestinal cancers
• Kidney cancer
• Prostate cancer
• Small cell lung cancer
• Non-small cell lung
• Other types of lung cancer
• Melanoma
Following five years as a clinical scientist at the MRC's clinical research centre in Northwick Park, Professor Dalgleish was appointed to the Foundation Chair in Oncology at the St George's University of London in 1991. There his main interest has been the immunology of cancer and the development of immunotherapies to treat, in particular, melanoma. He is a co-founder of Onyvax, a company set up in 1998 to make novel vaccines for common solid tumours, where he is currently Research Director.
Professor Dalgleish currently sits on eight editorial boards and is the author or co-author of peer-reviewed scientific papers and over 70 chapters in medical books. He is the co-editor of five medical books and has been on numerous grant committees and is currently on the European Commission Cancer Board.
Diseases, Medical Tests and Treatments
• Kidney
• Pancreatic and prostate cancers
• Melanoma (chemotherapy)
• Breast cancer
• Gastrointestinal cancers
• Urological cancers
• Lung
• Skin cancer
• Sarcoma cancer
• Upper gastrointestinal cancers
• Lower gastrointestinal cancers
• Kidney cancer
• Prostate cancer
• Small cell lung cancer
• Non-small cell lung
• Other types of lung cancer
• Melanoma
• Kidney
• Pancreatic and prostate cancers
• Melanoma (chemotherapy)
• Breast cancer
• Gastrointestinal cancers
• Urological cancers
• Lung
• Skin cancer
• Sarcoma cancer
• Upper gastrointestinal cancers
• Lower gastrointestinal cancers
• Kidney cancer
• Prostate cancer
• Small cell lung cancer
• Non-small cell lung
• Other types of lung cancer
• Melanoma
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Prof Angus Dalgleish
Education & training
-
2001–2007 MD · Medicine and Surgery
-
2007–2011 Residency · Oncology
Career & appointments
-
2011-09–2012-08 Junior consultant
Licenses & insurance
Medical licenses
— Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
Allianz Professional · 2,000,000 EUR coverage
· No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 2,805 |
| Annual physical exam | 99395 | 1,307 |
| Vaccination administration | 90471 | 747 |
| Minor procedure (skin) | 17110 | 2,724 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 30 min | in_clinic | 810.00 EUR |
| Minor procedure (skin) | 120 min | in_clinic | 540.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 8 · i10: 3
-
Validation of clinical scoring in Oncology
DOI: 10.5363/euroclin.2026.0 · PMID: 30413415 · cited by 29
-
Long-term follow-up of Oncology across
DOI: 10.7428/euroclin.2025.1 · PMID: 36022371 · cited by 39
-
Validation of clinical scoring in Oncology
DOI: 10.3326/euroclin.2024.2 · PMID: 35111599 · cited by 33
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — · EuroClinics Patient Choice · 2025 · regional
Society memberships
- WONCA Europe — Family Doctors — Member · since 2012
- national college of family doctors — Member · since 2012
- European Union of Medical Specialists (UEMS) — Member · since 2012
Patient reviews
- Bedside Manner
- 0.05
- Knowledge
- 0.08
- Wait Time
- 3.80
- Staff Friendliness
- 0.02
- Ease Of Appointment
- 4.00
- Value For Money
- 4.10
- Would Recommend Pct
- 4
-
★ 5 verified visit
“Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.”
-
★ 5 verified visit
“Took time to listen and reviewed all my previous results. I would absolutely recommend.”
-
★ 4 verified visit
“Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.”
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · professor.angus.dalgleish.2@euroclinics.example
